Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study

Maria T. Abreu, Christian von Tirpitz, Robert Hardi, Martin Kaatz, Gert Van Assche, Paul Rutgeerts, Emil Bisaccia, Sergi Goerdt, Stephen Hanauer, Robert Knobler, Peter Mannon, Lloyd Mayer, Thomas Ochsenkuhn, William J. Sandborn, Dennis Parenti, Kevin Lee, Walter Reinisch

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Background: Extracorporeal photopheresis (ECP) is effective in immune-mediated disorders. A prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ECP in patients with active Crohn's disease (CD) who were refractory to or intolerant of immunosuppressants and/or anti-TNF therapies. Methods: Patients with moderate-to-severely active CD (Crohn's Disease Activity Index [CDAI] 220-450 points) underwent 12 weeks of ECP treatment (Weeks 1-4: twice weekly, every week; Weeks 5-12: twice weekly, every other week). Clinical response was defined as a decrease in the CDAI of ≥100 points or remission (CDAI <150 points) at Week 12. Patients who responded at Week 12 could receive an additional 12 weeks of ECP treatment (twice weekly, every other week) in an extension study. Results: Twenty-eight patients were enrolled with a mean baseline CDAI score of 314 (range 207-457). At Week 12, 14 patients (50%) responded; 13 patients responded within 6 weeks. Seven patients (25%) attained remission by Week 12. Three of 5 patients with open fistulae at baseline had fistula closure. Response was similar among patients naïve to anti-TNF agents and patients who had previously been refractory or intolerant to anti-TNF agents. Of the 12 patients who entered the extension study, 9 (75%) maintained their response at Week 24. Conclusions: In patients with moderate-to-severely active CD who were refractory to or intolerant of immunosuppressants and/or anti-TNF agents, ECP was well tolerated and induced clinical response (50%) and remission (25%) in patients. Most patients were able to maintain a response with continued treatments.

Original languageEnglish (US)
Pages (from-to)829-836
Number of pages8
JournalInflammatory bowel diseases
Volume15
Issue number6
DOIs
StatePublished - 2009

Keywords

  • 8-methoxypsoralen
  • Anti-TNF therapy
  • Crohn's disease
  • Extracorporeal photopheresis
  • Immunomodulators

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study'. Together they form a unique fingerprint.

Cite this